HomeAI · summaries
Storia in 10 fonti
CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercehealthcare.com
CVS sues to challenge Tennessee's new PBM law
CVS has filed suit to challenge a Tennessee law that would bar pharmacy benefit managers from owning pharmacies in the state. | CVS has filed suit to challenge a Tennessee law…
- ·
biopharmadive.com
CVS obesity drug deal puts Lilly on equal footing with Novo
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
- ·
morningstar.com
CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
- ·
nbcnews.com
CVS Caremark will cover Lilly’s weight loss drug Zepbound once again
The pharmacy benefits manager also plans to add the weight loss pill Foundayo to its formulary next month.
- ·
cnbc.com
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.
- ·
qz.com
CVS Caremark adds Zepbound and Foundayo to formulary
The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options
- ·
fiercepharma.com
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets…
- ·
independent.co.uk
CVS expands access to blockbuster weight-drugs in surprise reversal
This move marks a pivotal shift for patients seeking access to these highly sought-after treatments
- ·
CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will
- ·
endpoints.news
Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook
Lilly's Foundayo and Zepbound gain CVS Caremark formulary coverage, expanding access for 90 million members at $25 monthly co-pays.
- ·
upi.com
CVS Caremark to cover Foundayo, Zepbound obesity drugs - UPI.com
CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several months, the companies said.
- ·
CVS, Walgreens and Walmart defeat opioid lawsuit brought by Florida hospitals
A Florida judge ruled in favor of CVS, Walgreens and Walmart in a lawsuit brought by 16 hospitals accusing the pharmacy retailers of flooding the state with opioids. | A Florida…